Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

News > Business News

Audio By Carbonatix

8:00 AM on Monday, January 12

The Associated Press

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 12, 2026--

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025.

Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the fiscal 2026 first quarter preliminary, unaudited revenue, or click https://investors.twistbioscience.com/events-and-presentations.

Twist will issue its financial results for the first quarter of fiscal 2026 before the opening of the market on February 2, 2026, and will hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

View source version on businesswire.com:https://www.businesswire.com/news/home/20260112290341/en/

CONTACT: For Investors:

Angela Bitting

SVP, Corporate Affairs

925-202-6211

[email protected] Media:

Amanda Houlihan

Communications Manager

774-265-5334

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA